SBIR/STTR Research Award
402 - RFP: N43-CM-87007-68 TOPIC 251: DEVELOPMENT OF ANTICANCER AGENTS REQUEST
Award amount
$149,558Program and phase
SBIR · Phase IAward year
2008Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- PROVID PHARMACEUTICALS INC.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- TNNMX4JCPCE8
- Solicitation number
- Not reported
- Topic code
- Not reported
Research abstract
This project aims to further develop 10-aryl deazaflavin compounds that have been shown to be inhibitors of HDM2's ubiquitin ligase.
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- TRAIL Upregulation by TIC10 Analogs
- F11R antagonists for atherosclerosis
- MEDICINAL CHEMISTRY LEAD OPTIMIZATION , (PHASE II) SBIR TOPIC 198
- Inhibitors of Protein Kinase A Localization in the Heart
- Design and Assay of DQ2 Inhibitors for Celiac Disease
Research funding history
11 SBIR/STTR records share this UEI (2002–2014). Reported award amounts total $1,990,429. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services